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with THIOMAB™ antibody technology delivers
a highly stable, potent and near homogeneous
THIOMAB™ antibody-drug conjugate (TDC)†
Joa˜o P. M. Nunes,a Vessela Vassileva,b Eiﬁon Robinson,a Maur´ıcio Morais, a
Mark E. B. Smith,a R. Barbara Pedley,b Stephen Caddick,a James R. Baker *a
and Vijay Chudasama *ac
Herein we demonstrate that conjugation of a next generation maleimide (NGM) to engineered cysteines in
a THIOMAB™ antibody delivers a THIOMAB™ antibody-drug conjugate (TDC) with a drug loading of ca. 2.
This TDC is highly stable in blood serum conditions, selective and potent towards HER2 expressing cell lines
and meets the current criteria for optimised antibody-drug conjugates (ADCs).Antibody-drug conjugates (ADCs) have emerged as targeted
therapeutics against cancer by combining the selectivity of the
antibody component with the potency of cytotoxic drugs. There
are two FDA-approved ADCs already on the market (Adcetris™
and Kadcyla™) and over 40 additional ADCs currently under-
going clinical trials.1–4
Classical methods of conjugation for producing ADCs
include lysine modication5 and cysteine modication via
reduction of solvent accessible disulde bonds followed by
reaction with maleimides.6 It has been recognised that both
methods generate heterogeneous mixtures of ADCs with
diﬀerent drug loadings and varied sites of attachment, resulting
in sub-optimal therapeutic indices and higher clearance
rates.7–13 Formation of higher drug-to-antibody ratio species
(DAR > 4) have narrower therapeutic indices.1,7,9,12,14 The latter
method also results in the loss of structural disulde bonds
which can lead to poor stability.7,9,14
The next generation of conjugation methods has aimed to
reduce heterogeneity by focusing on site-selectivity. Chemo-
enzymatic methods have been used for ADC synthesis such as
glycan modication,15–17 glutamine amidation18 and cysteine
oxidation to aldehyde tags.19 Site-selective disulde modica-
tion with small molecules has been achieved using next-London, London, WC1H 0AJ, UK. E-mail:
k; Tel: +44 (0)20 7679 2653; +44 (0)20
ndon, UK
boa), Faculty of Pharmacy, Universidade
SI) available: Conjugation and analysis
d 13C NMR spectra for synthesised
lysis, SEC analysis, ELISA analysis and
1039/c7ra04606e
32generation maleimides (NGMs),20–27 pyridazinediones
(PDs)28–32 and bis-sulfones.33,34 Site-specic reactivity has also
been accomplished through incorporation of non-natural ami-
noacids into proteins for bioorthogonal conjugation.10,35–39
The THIOMAB™ antibody technology platform uses site-
directed mutagenesis to incorporate cysteines into the anti-
body. Conjugation to a classical maleimide bearing the drug of
choice aﬀords a THIOMAB™ antibody-drug conjugate (TDC)
with full control over site reactivity and a precise drug-to-
antibody ratio (DAR).12,40–42 The technology also avoids issues
with some chemoenzymatic methods that can result in over
oxidation of aminoacids43 and aldehyde tag conversion to
unreactive gem-diols.44 TDCs have been demonstrated to
improve therapeutic indices and pharmacodynamics over ADCs
prepared by classical cysteine and lysine modication.11,12,42
Maleimides are rapid thiol-selective conjugation
reagents.45,46 However, the succinimide conjugates thus formed
can undergo retro-Michael reactions and scavenging with
albumin,47 resulting in premature drug release during blood
circulation.10,41,48 N-Alkyl succinimide conjugates can be stabi-
lised against retro-Michael reactions by hydrolysis to succi-
namic acid derivatives,49–51 which resulted in ADCs with
improved pharmacokinetics and in vivo eﬃcacy.41,51,52 Most N-
alkyl thiosuccinimide ADCs require prolonged hydrolysis (>16
h) at high pH (>8)41,51 which is not desirable from a process view
and can lead to deamidation and loss of payload.51 Hydrolysis
has been facilitated to under an hour by the inclusion of a basic
amine on the N-alkyl substituent near the point of attachment
to the thiosuccinimide52 or by using N-aryl substituents, but
these also come with limitations.1,25,49
We have previously shown that ADCs prepared via disulde
bridging with NGMs can be stabilised through hydrolysis.21 We
have also introduced monobromomaleimides (MBMs) as fastThis journal is © The Royal Society of Chemistry 2017
Scheme 1 Modiﬁcation of thio-trastuzumab with monobromomaleimide reagents (MBMs). (A) Outline of the 3-step method for thio-trastu-
zumab functionalisation with MBMs 1 and 2; (B) conjugation of MBMs to thio-trastuzumab and hydrolysis of conjugate under basic conditions;
(C) structure of MBM reagents 1 and 2.
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View Article Onlinereagents for conjugation to single cysteines.53 We envisaged
introducing a glycine spacer between the MBM and the valine–
citrulline self-immolative linker carrying monomethyl auri-
statin E (vc-PABC-MMAE) to enhance hydrolysis of the resulting
maleimide conjugate. Conjugation of this reagent to the THI-
OMAB™ antibody should create a highly stable and homoge-
neous TDC with a DAR of ca. 2 without a distinct hydrolysis step.
We chose to functionalise a thio-trastuzumab variant directed
against HER2 with an engineered cysteine on each light chain
(LC-V205C), obtained from Genentech (in a 3.67 mg mL1
solution in 50 mM Tris acetates solution). This THIOMAB™
antibody displays enhanced rate of thiosuccinimide hydrolysis
due to the positively charged environment surrounding the
mutant site.41However, succinimide conjugates can still undergo
retro-Michael before hydrolysing. By contrast NGMs mechanis-
tically cannot undergo retro-Michael by elimination. Thus,
NGMs oﬀer the advantage of a stable conjugation during
hydrolysis. Modication of thio-trastuzumab follows a 3 step
process: reduction of all solvent accessible disulde bonds, mild
reoxidation of native interchain disulde bonds and conjugationFig. 1 SDS-PAGE of thio-trastuzumab conjugation with MBM 1.
Fig. 2 Characterisation of TDC 3 by LC-MS. (A) Fragments generated
for reducing LC-MS; deconvoluted MS data for (B) unmodiﬁed thio-
trastuzumab, (C) unreduced TDC 3 and (D) reduced TDC 3.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 24828–24832 | 24829
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View Article OnlinewithMBMs 1 and 2 to aﬀord TDC 3 and thio-trastuzumab alkyne
conjugate (TAC) 4, respectively (Scheme 1, see ESI for details†).
Functionalisation of TAC 4 with AlexaFluor® 488 aﬀords thio-
trastuzumab uorophore conjugate (TFC) 5. Unlike previous
protocols, it was envisaged that hydrolysis of these NGM conju-
gates would be fast, and in situ, under our mildly basic conju-
gation conditions (pH 8).
MBM reagents 1 and 2 were prepared in a convergent
synthesis. Monobromomaleic anhydride was condensed with
glycine to aﬀord 2-(3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)acetic acid. Commercially available BocHN-vc-PABC-PNP
carbonate was coupled to MMAE or propargylamine by an
adapted protocol.6 Boc deprotection with TFA was followed by
amide bond formation with a bifunctional polyethylene glycol
spacer (PEG12). Another Boc deprotection and coupling to 2-(3-
bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid aﬀorded
MBM reagents 1 and 2 (see ESI for further details†).
We functionalised the thio-trastuzumab by adapting a liter-
ature protocol.12 Reduction of all solvent accessible disulde
bonds was carried out with tris-2-carboxyethyl phosphine
hydrochloride (TCEP), followed by reoxidation of native inter-
chain disulde bonds with dehydroascorbic acid (dhAA). Ell-
man's analysis following reduction and oxidation steps revealed
the expected 10 and 2 sulydryls per antibody respectively,
indicating there are two available cysteines per antibody for
conjugation (see ESI, Table S1†). Conjugation was carried out
using a modest excess of MBM 1 (4 eq., 2 eq. per cysteine) at pH
8 for 1 h at room temperature to aﬀord TDC 3. Ellman's analysis
aer conjugation and purication revealed negligible free
sulydryls (see ESI, Table S1†).Fig. 3 Fluorescence SEC-HPLC for TFC 5 incubated samples in blood
serum across 10 days.
Fig. 4 In vitro potency of TDC 3 and thio-trastuzumab on (A) SKBR-3 ce
TDC concentration.
24830 | RSC Adv., 2017, 7, 24828–24832Non-reducing SDS-PAGE gel revealed complete reduction
and reoxidation in the rst two steps (lanes 2 and 3, Fig. 1). No
fragmentation is visible following conjugation and purication
(lanes 4 and 5), suggesting that the resulting TDC 3 consists of
full mAb species alone. A reducing SDS-PAGE gel reveals that
the light chain of TDC 3 is shied to a higher mass indicating
that conjugation has taken place on the light chain (lane 7,
Fig. 1). Furthermore, it demonstrates that the conjugation is
resistant to harsh reducing conditions.
Non-reducing LC-MS analysis of TDC 3 revealed a thio-
trastuzumab conjugated with two maleamic acid PEG12-vc-
PABC-MMAE payloads (151 824 Da, calculated mass 151 819
Da, Fig. 2). TDC 3 was also analysed by LC-MS following
reduction of the interchain disulde bonds (TCEP, 10 eq.) and
capping of free sulydryls with maleimide (100 eq.). This
revealed a heavy chain with 3 maleimides (50 888 Da) and two
light chain species: one modied with one maleimide and one
maleamic acid PEG12-vc-PABC-MMAE payload as proton (25 418
Da, expected mass 25 416 Da) and sodium (25 443 Da, expected
25 438 Da) adducts, and another light chain modied with
maleimide alone (23 638 Da, expected mass 23 638 Da). Peak
integration demonstrates that almost all of the light chains
were successfully conjugated to MBM 1 and practically all of the
conjugates hydrolysed to maleamic acid. From the extent of
light chain conjugation we calculated a DAR of 1.8.
This value is in agreement with results from Ellman's anal-
ysis following conjugation (see ESI, Table S1†). This conrms
conjugation withMBM 1 took place on light chain alone (Fig. 2).
It also demonstrates that the maleimide conjugate hydrolysed
to the maleamic acid form as required for enhanced stability
during conjugation conditions without any further steps
required.
Size exclusion chromatography of TDC 3 showed that the
conjugate is composed predominantly of monomeric species
(>98%, see ESI, Fig. S5†). TDC 3 retains binding activity to HER2
(expressed in human cells, obtained from Sino Biological), as
determined by ELISA assay, demonstrating that conjugation
does not impact on receptor binding (see ESI, Fig. S6†). We also
prepared TFC 5 by conjugating TAC 4 with MBM 2, followed by
copper catalysed alkyne–azide cycloaddition (CuAAC) to
AlexaFluor® 488. TFC 5 was incubated in blood serum (human
serum, from human male plasma AB, USA origin, sterile-
ltered, obtained from Sigma-Aldrich) at 37 C over 10 days
and analysed by uorescence SEC-HPLC to assess the stability
of conjugation. No signicant transfer to albumin or decreasells, (B) HCC-1954 cells, and (C) MCF-7. Cell viability was plotted against
This journal is © The Royal Society of Chemistry 2017
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
0 
M
ay
 2
01
7.
 D
ow
nl
oa
de
d 
on
 2
1/
11
/2
01
7 
11
:2
8:
00
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinein antibody uorescence were observed over time, demon-
strating that our method of conjugation aﬀords a highly serum-
stable TDC (Fig. 3).
In possession of TDC 3 bearing MMAE, we next assessed in
vitro cytotoxicity by the MTT assay. HER2-positive human breast
cancer cell lines SKBR-3 and HCC-1954 were chosen and HER2-
negative cell line MCF-7 was used as a negative control (all cell
lines were obtained from the American Type Culture Collection
(ATCC)). All cell lines were sensitive to MMAE, with IC50 values
of 0.19 nM, 0.21 nM and 0.01 nM for SKBR-3, HCC-1954 and
MCF-7 respectively. Gratifyingly, TDC 3 was highly potent
against HER2-positive cell lines, with IC50 values of 0.14 nM and
0.31 nM for SKBR-3 andHCC-1954 respectively. TDC 3 displayed
minimal activity against the HER-2 negative MCF-7 cell line.
This demonstrates that TDC 3 displays potent cell-killing ability
in a targeted manner for HER2 expressing cell lines (Fig. 4).Conclusions
In conclusion, we have applied NGM technology as MBM
compounds for the functionalisation of single cysteines in
a thio-trastuzumab variant. We demonstrate that this applica-
tion aﬀords a TDC with a controlled DAR as full mAb species
that is highly stable, retains binding activity towards HER2 and
displays potent and selective cell kill ability. Moreover, the
mechanism for conjugate stabilisation via hydrolysis is shown
to naturally take place during standard conjugation conditions,
revealing an advantage from a process and eﬃciency point of
view. NGM technology is entirely compatible with the current
generation of superior engineered cysteine THIOMAB™ anti-
body variants. The TDC thus prepared with NGM technology ts
all current criteria for industry-relevant ADCs.Acknowledgements
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